Proteomics-based prediction of clinical response in acute myeloid leukemia

Experimental Hematology

Volumn 37, Issue 7, 2009, Pages 784-790

  Albitar, Maher ^a   Potts, Steven J ^b   Giles, Francis J ^c   O'Brien, Susan ^d   Jilani, Iman ^a   Donahue, Amber C ^a   Estey, Elihu H ^d   Kantarjian, Hagop ^d  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b Aperio Technologies   (United States)

^c University of Texas Health Science Center at San Antonio   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; IDARUBICIN;

ACCURACY; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; DECISION TREE; DRUG RESPONSE; ELUTION; HUMAN; LABORATORY TEST; MONOCYTE; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROTEOMICS; REPRODUCIBILITY OF RESULTS;

EID: 67049134640     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.03.011     Document Type: Article

References (19)

1. Stone R.M., O'Donnell M.R., and Sekeres M.A. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program (2004) 98-117
2. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92 (1998) 2322-2333
3. Amin H.M., Yang Y., Shen Y., et al. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias. Leukemia 19 (2005) 1567-1572
4. Albitar M., Do K.A., Johnson M.M., et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 101 (2004) 999-1008
5. Giles F.J., Vose J.M., Do K.A., et al. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol 123 (2003) 850-857
6. Jilani I., Estey E., Manshuri T., et al. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. Leukemia 17 (2003) 114-119
7. Manshouri T., Do K.A., Wang X., et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101 (2003) 2507-2513
8. Rogers A., Joe Y., Manshouri T., et al. Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. Blood 103 (2004) 2799-2801
9. Albitar M., Potts S.J., Giles F.J., et al. Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia. Cancer 106 (2006) 1587-1594
10. Czibere A., Grall F., and Aivado M. Perspectives of proteomics in acute myeloid leukemia. Expert Rev Anticancer Ther 6 (2006) 1663-1675
11. Kiehntopf M., Siegmund R., and Deufel T. Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. Clin Chem Lab Med 45 (2007) 1435-1449
12. Anderson N.L., Polanski M., Pieper R., et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 3 (2004) 311-326
13. Chertov O., Simpson J.T., Biragyn A., Conrads T.P., Veenstra T.D., and Fisher R.J. Enrichment of low-molecular-weight proteins from biofluids for biomarker discovery. Expert Rev Proteomics 2 (2005) 139-145
14. Hanash S.M., Pitteri S.J., and Faca V.M. Mining the plasma proteome for cancer biomarkers. Nature 452 (2008) 571-579
15. Wiemer J.C., and Prokudin A. Bioinformatics in proteomics: application, terminology, and pitfalls. Pathol Res Pract 200 (2004) 173-178
16. Cheson B.D., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21 (2003) 4642-4649
17. Lightfoot J., Hitzler J.K., Zipursky A., Albert M., and Macgregor P.F. Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down syndrome. Leukemia 18 (2004) 1617-1623
18. Aivado M., Spentzos D., Germing U., et al. Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci U S A 104 (2007) 1307-1312
19. Chen G., Gharib T.G., Huang C.C., et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 1 (2002) 304-313